Gaviscon Advance oral suspension peppermint

Land: Storbritannia

Språk: engelsk

Kilde: MHRA (Medicines & Healthcare Products Regulatory Agency)

Aktiv ingrediens:

Sodium alginate; Potassium bicarbonate

Tilgjengelig fra:

Forum Health Products Ltd

INN (International Name):

Sodium alginate; Potassium bicarbonate

Dosering :

100mg/1ml ; 20mg/1ml

Legemiddelform:

Oral suspension

Administreringsrute:

Oral

Klasse:

No Controlled Drug Status

Resept typen:

Valid as a prescribable product

Produkt oppsummering:

BNF: 01010201; GTIN: 5000158065635 5000158064515

Informasjon til brukeren

0.0 mm
100%
EAN 13
5000158065109
22.9 mm
30 microns
N/A
26.1 mm
BARCODE INFO
Barcode Type:
Barcode Number:
Magnification:
Truncated By:
Full Height:
Bar Height (Smallest Bar):
BWR:
Encoded Data:
Trident Reference No:
ZEN Ref:
Action:
Brand:
Category:
Segment Group:
Segment:
Pack Size:
Market/Country:
Date:
Component Code
(2D if applicable)
:
Parent Technical Packaging
Specification:
Finished Goods Code:
Supply Point:
3rd Party Code
Pharmacode No/NE:
Edgemark Position:
CAD Cam Ref:
Printer:
Substrate:
N/A
N/A
RB Hull
NA
N/A
Gaviscon
Adult
Advance Liquid
Peppermint
300ml
RB391858
Please note that any low resolution paper Canon colour copies
associated with this job should be referred to for content, layout
and colour separation only.
STUDIO USE ONLY
v2.0
Sm•Art check results:
Cutter
Guides
Technical & Non Printing Items
Cutter 2 (if applicable)
Guides 2 (if applicable)
Multi Packaging Solutions (Bourne, UK)
G-Lbl-D8340700-70x177.8mm PPTD1736
TR1686077
PP-White SA
UK
16/01/20
B
Mel Hall
RB00000
G=2; O=0; R=1; - MH - 16/01/20 14:35:33
RB Artwork and
Print Specification
D8340700
Artwork Type:
RB Artwork Creation IDM
10
mm
20
30
40
50
60
70
80
90
100
110
120
130
140
150
160
170
180
190
200
210
220
230
240
250
1
FLX
PANTONE Reflex Blue C
2
FLX
PANTONE 320 C
3
FLX
PANTONE 7488 C
4
FLX
PANTONE 185 C
5
FLX
Process Yellow
6
FLX
Braille
7
FLX
VRN-HighGlossUV+Opt Brightener
8
FLX
Release Varnish
Colours (Label _Peel Read)
RBH Contact:
James Hart
Connaught House, Connaught Road,
Kingswood Business Park, Hull, HU7 3AP, England.
T: [phone]
UNDER NO CIRCUMSTANCES SHOULD THIS
ARTWORK BE ALTERED WITHOUT PRIOR
PERMISSION FROM TRIDENT.
CUSTOMER INFO:
Important Please Read:
Retouching has not been
approved. Data will not be
created for this job until all
retouching is approved.
CUSTOMER INFO:
Minimum Point Size =
_Leaflet Copy = 9pt_
7.00pt
GAVISCON ADVANCE
PEPPERMINT FLAVOUR
ORAL SUSPENSION
T B R 2 6 7 4 - D 8 3 4 0 7 0 0 – E n g l i s h
GAVISCON ADVANCE PEPPERMINT FLAVOUR ORAL
SUSPENSION.
Sodium alginate and potass

Preparatomtale

SUMMARY OF PRODUCT CHARACTERISTICS
1
NAME OF THE MEDICINAL PRODUCT
Gaviscon Advance Peppermint Flavour Oral Suspension
2
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each 10 ml dose contains sodium alginate 1000 mg and potassium
hydrogen
carbonate 200 mg. 1 ml contains sodium alginate 100 mg and potassium
hydrogen carbonate 20.0 mg.
Each 10 ml dose is equivalent to two 5 ml measuring spoons.
Excipient(s) with known effect:
Methyl parahydroxybenzoate E218
Propyl parahydroxybenzoate E216
Sodium
For a full list of excipients, see section 6.1.
3
PHARMACEUTICAL FORM
Oral suspension.
Off-white viscous suspension.
4
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Treatment of symptoms resulting from the reflux of acid, bile and
pepsin into the
oesophagus such as acid regurgitation, heartburn, indigestion
(occurring due to the
reflux of stomach contents), for instance, after gastric surgery, as a
result of hiatus
hernia, during pregnancy, accompanying reflux oesophagitis, including
symptoms of
laryngopharyngeal reflux such as hoarseness and other voice disorders,
sore throats
and cough. It can also be used to treat the symptoms of
gastro-oesophageal reflux
during concomitant treatment with or following withdrawal of acid
suppressing
therapy.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Adults and children 12 years and over: 5-10 ml after meals and at
bedtime
(one to two 5 ml measuring spoons).
Children under 12 years: Should be given only on medical advice.
Elderly: No dose modification is required for this age group.
Hepatic Impairment: No dose modification necessary.
Renal Insufficiency: Caution if highly restricted salt diet is
necessary (see
section 4.4).
4.3
CONTRAINDICATIONS
The medicinal product is contraindicated in patients with known or
suspected
hypersensitivity to the active substances or to any of the excipients
listed in section
6.1, including methyl parahydroxybenzoate (E218) and propyl
parahydroxybenzoate
(E216) (see section 4.4).
4.4
SPECIAL WARNINGS AND PRECAUTIONS FOR USE
If symptoms do not improve after 7 d